TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18820657
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 20 mg triamcinolone acetonide with topical 1% prednisolone acetate
Study: 18820657
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 500 mg methylprednisolone with topical 1% prednisolone acetate
Study: 17302057
Drug: Drug-pair group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-pair group
Study: 15118485
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Delta-9-tetrahydrocannabinol (THC)
Study: 15118485
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg THC combined with 5 mg cannabidiol (CBD)
Study: 15118485
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg THC combined with 15 mg CBD
Study: 9542820
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (beta-adrenoceptor blockers and/or thiazide diuretics)
Study: 2577394
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) administration of 30 mg/l vancomycin for 10 days
Study: 2577394
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of 1 gram of vancomycin (2 infusions: first on diagnosis day, second 7 days later)
Study: 806789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.10 mg reserpine, 10 mg mefruside, and 125 mg alpha-methyldopa
Study: 806789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.15 mg reserpine, 15 mg mefruside, and 150 mg inositol nicotinate
Study: 28664349
Drug: Citrulline/Malate (stimol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline/Malate (stimol) 3 times a day as 1 g for breakfast, 1 g for lunch, and 1 g for dinner
Study: 28664349
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage and timing as stimol)
Study: 26177810
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once a day for thromboprophylaxis
Study: 26177810
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of deep and superficial blocks
Study: 23169243
Drug: FIT in
Normalized name: First Aid Fit Industrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT in combination with a feces collection paper (n=5129)
Study: 18305080
Drug: Low-dose intrathecal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intrathecal opioid (LITO): morphine 5 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Study: 18305080
Drug: High-dose intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intrathecal opioid (HITO): morphine 15 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Study: 16421677
Drug: Lidocaine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.0 mg.kg(‐1) (group L1)
Study: 16421677
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg(‐1) (group L2)
Study: 12742805
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril and indapamide)
Study: 12953851
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril and indapamide) with recurrent stroke
Study: 4008686
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (gelatin capsules containing microcrystalline 8‐MOP with particle size between 20 mu and 30 mu)
Study: 4008686
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (microcrystalline 8‐MOP in an emulsion base)
Study: 4008686
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (gelatin capsules containing 8‐MOP with a mean particle size of 200 mu)
Study: 30208456
Drug: Levofloxacin prophylaxis
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin prophylaxis during 2 chemotherapy cycles for acute leukemia (n=100)
Study: 26421957
Drug: EE/GSD patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/GSD patch
Study: 25453582
Drug: EE/NGMN patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/NGMN patch
Study: 22198974
Drug: Inhaled mannitol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol, 400 mg twice a day
Study: 22198974
Drug: Inhaled mannitol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol, 50 mg twice a day (control)
Study: 16971160
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy dynamometer (100N force)
Study: 11350770
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training combined with rhGH administration
Study: 8198264
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg butorphanol (Group A)
Study: 8198264
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg butorphanol (Group B)
Study: 8198264
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg butorphanol (Group C)
Study: 8198264
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL normal saline (Group D)
Study: 29696917
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with acupoint catgut embedding sequential therapy
Study: 23678828
Drug: Alpha lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid treatment for four months
Study: 16800100
Drug: Nevirapine/lamivudine/stavudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine/lamivudine/stavudine combination tablet (200 mg/150 mg/30 mg)
Study: 16800100
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg, Lamivudine 150 mg, and Stavudine 30 mg administered concurrently as separate formulations
Study: 12903886
Drug: Gln-enriched enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln-enriched enteral nutrition (0.35 g gln/kg body weight/d)
Study: 12903886
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral formulation
Study: 11191542
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody to IL-5 (SB-240563) at 10 mg/kg
Study: 11191542
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody to IL-5 (SB-240563)
Study: 9167750
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) administered intravenously
Study: 6418374
Drug: Oral trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim-sulfamethoxazole plus erythromycin (TMZ-E)
Study: 27317704
Drug: Levosimendan treatment
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan treatment
Study: 20055785
Drug: Nitroimidazole antibiotics
Normalized name: 2-methyl-5-nitroimidazole-1-ethanol
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitroimidazole antibiotics (metronidazole, ornidazole)
Study: 18522729
Drug: Combined written
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined written and oral information (N = 278)
Study: 18522729
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information alone (N = 299)
Study: 18522729
Drug: Combined written
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined written and oral information
Study: 2039194
Drug: Temafloxacin 100
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 100 mg
Study: 1662885
Drug: Temafloxacin 200
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 200 mg
Study: 1662883
Drug: Temafloxacin 400
Normalized name: temafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 400 mg
Study: 1662880
Drug: Temafloxacin 600
Normalized name: temafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 600 mg
Study: 2039194
Drug: Temafloxacin 800
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 800 mg
Study: 2039194
Drug: Temafloxacin 1000
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 1000 mg
Study: 2039194
Drug: Temafloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin (all doses)
Study: 6861436
Drug: Methadone doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone doses (0, 1, 5, 10, 25, or 50 mg)
Study: 25014686
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin and 40 mg of laropiprant
Study: 20196846
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (penicillin V)
Study: 31134657
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg, twice daily for 5 days)
Study: 10908773
Drug: Clindamycin 100
Normalized name: clindamycin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 100 mg vaginal ovules (intravaginally for 3 days) plus placebo capsules (orally twice daily for 7 days)
Study: 10908773
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg (two 250 mg capsules orally twice daily for 7 days) plus placebo ovules (intravaginally for 3 days)
Study: 10908773
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment group
Study: 3901562
Drug: Verapamil retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil retard preparation 240 mg b.i.d.
Study: 3901562
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard preparation 20 mg b.i.d.
Study: 28528340
Drug: Hypocaloric high‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric high‐protein diet (1.2‐1.4 g / kg body weight reference / day)
Study: 26169611
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T)
Study: 21561900
Drug: AZD1305 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 (50 mg/h)
Study: 21561900
Drug: AZD1305 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 (100 mg/h)
Study: 21561900
Drug: AZD1305 (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 (130 mg/h)
Study: 21561900
Drug: AZD1305 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1305 (180 mg/h)
Study: 11131366
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 1.7 g of EPA plus 1.15 g of DHA/day (as Maxepa capsules) for 28 days
Study: 11131366
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with Maxepa capsules
Study: 7854376
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg per day)
Study: 1727236
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in successful treatment; 0.5 mg per kilogram in treatment failure)
Study: 26909669
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg daily
Study: 22088980
Drug: Clopidogrel 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 225 mg daily
Study: 22088980
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg daily
Study: 25138079
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IOERT) using electrons
Study: 25138079
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (EBRT)
Study: 25138079
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) using 50-kV X-rays
Study: 22235820
Drug: Lisinopril (n=8904)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (n=8904)
Study: 19224415
Drug: Volar transposition
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volar transposition of the ulnar nerve (subcutaneous or submuscular technique)
Study: 19224415
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (prevention of exposure to external noxes)
Study: 10771928
Drug: PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T vaccine in association with DPT vaccine at different sites
Study: 10771928
Drug: PRP‐T and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T and DPT both vaccines at the same site mixed in the same syringe
Study: 10771928
Drug: PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T vaccine
Study: 2883715
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg twice daily
Study: 2883715
Drug: dexchlorpheniramine 6
Normalized name: dexchlorpheniramine 6 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexchlorpheniramine 6 mg twice daily
Study: 30897999
Drug: Diabetes mellitus
Normalized name: diagnostic,monitoring agents for diabetes mellitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes mellitus requiring treatment
Study: 27701683
Drug: Saffron (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (30 mg/day)
Study: 15812262
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg/day)
Study: 21493022
Drug: Estrogen therapy-aerobic
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy-aerobic training (ET-AT)
Study: 23942244
Drug: Estrogen therapy-control
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy-control
Study: 22769041
Drug: Augmented Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Cognitive Behavioural Therapy (CBT) intervention, which includes principles of recognizing, registering, and altering negative thoughts, augmented with direct in-vivo activation by occupational or movement therapists.
Study: 19640972
Drug: High cruciferous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cruciferous vegetable diet (14 g cruciferous vegetables/(kg body weightd))
Study: 10379619
Drug: Zolpidem (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5, 10, 20 mg/70 kg)
Study: 10379619
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25, 0.5 mg/70 kg)
Study: 8537264
Drug: Dirithromycin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin, 500 mg once daily for 5 days
Study: 8537264
Drug: Clarithromycin, 250
Normalized name: Clarithromycin, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 250 mg twice daily for 7 days
Study: 28818674
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) administered 24 hours prior to surgery
Study: 26428278
Drug: Palm date
Normalized name: date palm pollen extract
DrugBank: Phoenix dactylifera pollen (DB10950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm date consumption (seven dates, approximately 50 g)
Study: 26428278
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maltodextrin‐dextrose, 37·1 g)
Study: 23434504
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (40 IU 4 times per day)
Study: 21287538
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata (BS) 4200 mg/day
Study: 23579010
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy with Defibrillator (CRT-D)
Study: 10893915
Drug: Breastfeeding support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breastfeeding support including anticipatory counseling and monthly clinical follow-up
Study: 1342280
Drug: Nutrition supplements
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition supplements (calcium, magnesium, potassium, fish oil)
Study: 31535213
Drug: 136.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 136.6 mg isoflavones (as aglycone equivalents)
Study: 30466866
Drug: EPA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (2 g per day)
Study: 30466866
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg per day)
Study: 30466866
Drug: EPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA plus Aspirin
Study: 24071754
Drug: CRAFT family
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRAFT family education program (6 weekly 2 hour sessions)
Study: 20160396
Drug: Non-statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin treatment
Study: 10895748
Drug: i.m. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. ketamine 0.5-0.6 mg kg-1
Study: 10895748
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine 0.1-0.15 mg kg-1
Study: 4076532
Drug: Cimetropii bromidum
Normalized name: Clidinii Bromidum
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetropii bromidum (10 or 20 mg i.v.)
Study: 29664851
Drug: Formal outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formal outpatient physical therapy (PT)
Study: 20582493
Drug: T8 floating
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: T8 floating tablets
Study: 20582493
Drug: Immediate-release tablets
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablets (Vastrel® 20 mg)
Study: 3937005
Drug: Tocainide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide infusion
Study: 3937005
Drug: Oral tocainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tocainide therapy
Study: 30761795
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (Androgel) at a daily dose of 5 g (1 sachet)
Study: 30761795
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (Androgel) at a daily dose of 10 g (2 sachets)
Study: 30761795
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (exercise, diet, multivitamins)
Study: 27571129
Drug: Triple intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple intrathecal therapy (TIT)
Study: 21083596
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg/day
Study: 24121146
Drug: rabeprazole 5
Normalized name: RABEprazole 5 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 5 mg
Study: 18501262
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily of the SSRI antidepressant paroxetine
Study: 10475292
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg i.v. and glycopyrrolate 0.5 mg i.v. for reversal of residual neuromuscular blockade
Study: 10475292
Drug: No neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neostigmine administration
Study: 8542854
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus buprenorphine (7.2 mg kg‐1 of buprenorphine with 1.8 mg kg‐1 of bupivacaine)
Study: 8542854
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (1.8 mg kg‐1)
Study: 28481967
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab at randomization
Study: 28481967
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by bevacizumab after disease progression (PD)
Study: 22563991
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion activities (intervention)
Study: 21282542
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d